PHILADELPHIA--(BUSINESS WIRE)--Avid Radiopharmaceuticals, Inc. today announced the appointment of Christopher J. Bunting as the company’s Vice President, Marketing and Sales. In this role, Mr. Bunting will be responsible for the commercialization of 18F-AV-45 (AV-45), the most advanced F-18 compound in development for imaging amyloid plaque in the brain associated with Alzheimer’s disease.
